The ability to accurately detect IDH1/IDH2 mutation status and 1p19q co-deletion in a single test enhances lab efficiency and reduces the need for additional testing of samples having limited material, Although further validation of this DNA methylation epi-signature is required, it has the potential to refine the utility of WGMA to predict IDH1/IDH2 mutations status in gliomas, thus enhancing patient care through improved diagnostic yield and accuracy compared to single analyte IDH1/IDH2 or 1p19q tests. The gene discussed is IDH1; the disease is central nervous system cancer.